Ropinirole in Gilles de la Tourette syndrome.
The effects of treatment with ropinirole (0.25 to 0.5 mg bid) were examined using an open-label design for 8 weeks in 15 subjects with Gilles de la Tourette syndrome (GdlT). All patients completed the study, and most showed an improvement in their tics during treatment. Low-dose ropinirole may improve the motor features in GdlT, but further controlled studies are necessary.
Anca
Marietta H
MH
Department of Neurology, Tel-Aviv Medical Center, and the Sieratzki Chair of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Giladi
Nir
N
Korczyn
Amos D
AD
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D018491:Dopamine Agonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D005879:Tourette Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
D018491:Dopamine Agonists; D007211:Indoles; C046649:ropinirole